Ayse Sesin Kocagoz

Ayse Sesin Kocagoz

Auto-generated profile, based on publicly available information

Ayse Sesin Kocagoz

Acibadem Altunizade Hospital, Infectious Disease Unit, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2020 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
CIHAN TASTANCIHAN TASTAN
CIHAN TASTAN
BYBulut Yurtsever
Bulut Yurtsever
GKGözde Sir Karakuş
Gözde Sir Karakuş
DKDerya Di̇lEk Kançaği
Derya Di̇lEk Kançaği
SDSevda Demir
Sevda Demir
EOErcüment Ovali
Ercüment Ovali
The novel coronavirus pneumonia, which was named later as coronavirus disease 2019 (COVID-19), is caused by the severe acute respiratory syndrome coronavirus 2, namely SARS-CoV-2. It is a positive-strand RNA virus that is the seventh coronavirus known to infect humans. The COVID-19 outbreak presents enormous challenges for global health behind the pandemic outbreak. The first diagnosed patient in Turkey has been reported by the Republic of Turkey Ministry of Health on March 11, 2020. In May, over 150,000 cases in Turkey, and 5.5 million cases around the world have been declared. Due to the urgent need for a vaccine and antiviral drug, isolation of the virus is crucial. Here, we report 1 of the first isolation and characterization studies of SARS-CoV-2 from nasopharyngeal and oropharyngeal specimens of diagnosed patients in Turkey. This study provides an isolation and replication methodology,and cell culture tropism of the virus that will be available to the research communities.

1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
RDRıdvan Dumlu
Rıdvan Dumlu
NUNeval yurttutan uyar
Neval yurttutan uyar
MAMeltem Ayaş
Meltem Ayaş
NANi̇lAy Aksoy
Ni̇lAy Aksoy
NÖNur Öztürk
Nur Öztürk
AKAyşe Sesi̇n Kocagöz
Ayşe Sesi̇n Kocagöz
Background/aim: Our study investigated the susceptibility rate of ceftazidime-avibactam and the risk factors associated with its resistance by analyzing gram-negative bacteria isolated from various patient samples. Materials and methods: Between March and November 2020, 1119 gram-negative bacteria strains were isolated from patient samples in Acıbadem Healthcare Group hospitals; ceftazidime-avibactam susceptibility results were evaluated using a 10/4µg (Oxoid, UK) disc and evaluated according to Eucast 2020 recommendations. Patient and isolate characteristics that could be risk factors were retrospectively investigated and statistically analyzed using SPSS 25.0. Results: Male patients made up 52% (n = 581) of the study's total patient population, and they averaged 55.5 ± 24.9 years old. Of 1119 gram-negative strains culture and antibiogram, 1023 (91.4%) were sensitive to ceftazidime-avibactam. An increased risk of resistance was observed with female gender (OR = 2.29; CI 95% [1.45-3.61]; p < 0.05), Pseudomonas aeruginosa (OR = 1.67, CI 95% [1.03-2.7]; p < 0.05), the presence of multidrug-resistance (MDR) (OR = 4.07, CI 95% [2.47-6.7]; p < 0.05) pandrug-resistance (PDR) (OR = 12, (CI) 95% [9.9-14.7] ]; p < 0.05) and admission to intensive care unit (ICU) (OR = 1.89, CI 95% [1.22-2.93]; p < 0.05). Conclusion: The resistance rate of ceftazidime-avibactam was found to be 8.6%, and it was thought that resistant strains produced metallo-ß-lactamase (MBL) type carbapenemase. Risk factors were female gender, Pseudomonas aeruginosa, MDR, PDR, and admission to ICU. Therefore, studying the ceftazidime-avibactam susceptibility test together with gram-negative bacteria identification, especially in groups at risk for resistance, is one of the important factors that can positively affect the success of treatment.

28 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RTRaife Dilek Turan
Raife Dilek Turan
CIHAN TASTANCIHAN TASTAN
CIHAN TASTAN
DKDerya Dilek Kancagi
Derya Dilek Kancagi
BYBulut Yurtsever
Bulut Yurtsever
GKGozde Sir Karakus
Gozde Sir Karakus
GSGuldal Suyen
Guldal Suyen
The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A, oral polio vaccine, and smallpox proved to be reliable approaches for immunization for prolonged periods. During the pandemic, we produced an inactivated SARS-CoV-2 vaccine candidate, having the advantages of being manufactured rapidly and tested easily in comparison with recombinant vaccines. In this study, an inactivated virus vaccine that includes a gamma irradiation process for the inactivation as an alternative to classical chemical inactivation methods so that there is no extra purification required has been optimized. The vaccine candidate (OZG-38.61.3) was then applied in mice by employing the intradermal route, which decreased the requirement of a higher concentration of inactivated virus for proper immunization, unlike most of the classical inactivated vaccine treatments. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 10 13 or 10 14 viral copy per dose) of OZG-38.61.3 was initially determined in Balb/c mice. This was followed by testing the immunogenicity and protective efficacy of OZG-38.61.3. Human ACE2-encoding transgenic mice were immunized and then infected with a dose of infective SARS-CoV-2 virus for the challenge test. Findings of this study show that vaccinated mice have lower SARS-CoV-2 viral copy number in oropharyngeal specimens along with humoral and cellular immune responses against the SARS-CoV-2, including the neutralizing antibodies similar to those shown in Balb/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.

4 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
GKGozde Sir Karakus
Gozde Sir Karakus
CIHAN TASTANCIHAN TASTAN
CIHAN TASTAN
DKDerya Dilek Kancagi
Derya Dilek Kancagi
BYBulut Yurtsever
Bulut Yurtsever
GTGamze Tumentemur
Gamze Tumentemur
EOErcument Ovali
Ercument Ovali
COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1 (V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice.

30 April 2021 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
ASAral Sürmeli
Aral Sürmeli
ÖBÖykü Beyaz
Öykü Beyaz
EKElif Sitre Koç
Elif Sitre Koç
YGYasemin Gündogdu
Yasemin Gündogdu
ÇÇÇaglar Çuhadaroglu
Çaglar Çuhadaroglu
SKSesin Kocagöz
Sesin Kocagöz
Objective: Information on characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients in Turkey is limited. We aimed to describe the characteristics and outcomes of patients hospitalised with COVID-19 and compare patients who required intensive care unit (ICU) admission with those who did not require it. Materials and Methods: This retrospective cross-sectional study was conducted in a tertiary care hospital in Istanbul. A total of 215 patients hospitalised with COVID-19 between 9 March 2020 and 30 April 2020 were included. Demographic, clinical, laboratory and radiological data on admission and outcomes were analysed. The main outcomes were COVID-19 ward or ICU hospitalisation, invasive mechanical ventilation requirement, discharge, or death. Presenting characteristics were compared between patients who required ICU admission with those who did not require it. Results: Among 215 patients, 64% were male, and the median age was 53. The most prevalent comorbidity was hypertension, followed by diabetes mellitus and coronary artery disease. The prevalence of comorbidities and the median age was higher in patients in ICU. The most common presenting symptom was fever (72%). C-reactive protein (CRP), lactate dehydrogenase (LDH), neutrophil and lymphocyte count, ferritin, and d-dimer levels were significantly different between ICU and non-ICU patients. However, in the final logistic model, among presenting symptoms, initial radiographs and laboratory tests, having dyspnea, high CRP and LDH were significantly associated with ICU admission. Conclusion: Of 215 hospitalised patients with COVID-19, 17% of patients required ICU admission, and the mortality rate was 4.4%. Older age, having coronary artery disease, high levels of CRP, LDH, and presenting with dyspnea were significantly associated with ICU admission. Keywords: Infections, Pneumonia, Critical Care

30 December 2021 in Turkish Journal of Intensive Care
Verified
Journal Article
Closed access
LDLerzan Dogan
Lerzan Dogan
NANazire Afşar
Nazire Afşar
DKDilaver Kaya
Dilaver Kaya
ZSZeynep Tugce Sarikaya
Zeynep Tugce Sarikaya
OMOrkhan Mammadov
Orkhan Mammadov
İAİbrahim Özkan Akıncı
İbrahim Özkan Akıncı
Amaç: Koronavirüs hastalığı-2019’un (COVID-19) neden olduğu merkezi sinir sistemi tutulumu, artan morbidite ve mortalite ile ilişkili bulunmuştur. Derin sedatize ve mekanik ventilasyon desteği uygulanan yoğun bakım hastalarında nörolojik semptomları değerlendirmek ciddi bir zorluktur, bu nedenle ventilatörden ayırma aşamasına gelene kadar yoğun bakım hekimi bu semptomlardan habersiz kalabilmektedir. Çalışmanın amacı, kritik yoğun bakım hastalarında COVID-19 ilişkili bilinç bozukluğu için potansiyel prognostik prediktörlerin belirlenmesidir. Gereç ve Yöntem: Çalışma retrospektif, çok merkezli ve gözlemsel olarak dizayn edilmiştir. Beş hastanenin yoğun bakım ünitelerine 11 Mart 2020 ve 18 Eylül 2020 tarihleri arasında kabul edilen COVID-19 hastaları dahil edilmiştir. Hastalar iki grupta değerlendirilmiştir: Bilinç bozukluğu olan ve bilinç bozukluğu olmayan hastalar. Bulgular: Bilinç bozukluğu olan hastaların yaş ortalaması daha düşük (p=0,001) ve daha fazla laboratuvar anormalliğine sahip bulunmuştur; ferritin (p=0,003), C-reaktif protein seviyeleri (p=0,001), prokalsitonin (p=0,019) ve D-dimer (p=0,001). Ayrıca bilinç bozukluğu olan 29 hastanın 14’ünde (%48) patolojik manyetik rezonans görüntüleme bulguları tespit edildi. Sonuç: Yoğun bakımda COVID-19 hastaları nörolojik komplikasyon riskini belirlemek için hiperenflamasyon belirtileri açısından taranmalıdır. Erken tanı ve spesifik tedavinin başlatılması ile daha iyi sonuçlar alınabilecektir.